Lehdistötiedote17.03.2025 klo 13.05BioStock: Last trading day for Abliva - the company leaves Nasdaq Stockholm
Pörssitiedote03.03.2025 klo 14.10Delisting of the shares of Abliva: last day of trading 17 March 2025
Pörssitiedote25.02.2025 klo 10.50Abliva applies for delisting and will convene an extraordinary general meeting
Pörssitiedote15.12.2024 klo 21.00Statement by the Board of Directors of Abliva regarding the public cash offer from Pharming
Lehdistötiedote09.12.2024 klo 09.32Abliva Announces Publication of Results from Phase 1a/b Study of KL1333 in the Scientific Journal Brain
Lehdistötiedote04.11.2024 klo 12.00Abliva will present at the BioStock Life Science Summit, November 21
Lehdistötiedote16.09.2024 klo 09.30Join Abliva for World Mitochondrial Disease Week 2024, September 16 – 22
Lehdistötiedote26.08.2024 klo 09.46BioStock: Abliva's CEO - We are the leading programme in mitochondrial disease
Lehdistötiedote24.07.2024 klo 12.57Abliva's CEO to BioStock: "One step closer to a marketed medicine"
Pörssitiedote19.07.2024 klo 09.30Positive interim analysis in Abliva's FALCON study triggers convertible loan conversion
Pörssitiedote18.07.2024 klo 23.22Abliva Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial Disease